In TP53 mutant disease, APR‐246 (eprenetapopt), a novel drug that promotes refolding of TP53 and restoration of function, initially had encouraging results in a phase Ib/II clinical trial in combination with azacitidine (at 10.5 months, 45 patients with AML or MDS overall response rate [ORR] was 87%, CR rate of 61%) [92]. Here, TP53 is linked to myelodysplastic syndrome.